Most Read Articles
19 Sep 2018
In advanced-stage, newly diagnosed classical, CD30-positive Hodgkin lymphoma (HL), front-line therapy has resulted in durable remission rates in up to 70–90% of patients, although approximately 25–30% of advanced stage HL patients are refractory or relapse following first-line treatment with ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) chemotherapy.1–3 The standard of care for patients with relapsed or refractory (r/r) classical HL is salvage therapy using second-line high-dose chemotherapy (HDCT), followed by autologous haematopoietic stem cell transplant (ASCT) in eligible patients, which can induce a complete remission (CR) in about 50% of patients.4 Nevertheless, the prognosis of patients who relapse after the salvage HDCT/ASCT is exceedingly poor, with a median survival duration of approximately 1.2 years.5
09 Sep 2016
A German longitudinal study shows that Hodgkin’s lymphoma survivors experience acute and persistent fatigue regardless of tumour stage and treatment.
Natalia Reoutova, 6 days ago
Reduced conditioning intensity is significantly associated with increased relapse, decreased disease-free survival (DFS), and decreased overall survival (OS) in acute myeloid leukaemia (AML) patients with measurable residual disease (MRD), a new analysis of a phase III randomized clinical trial has shown.

Dermoscopy aids in detecting paediatric melanoma

18 Jan 2018

Dermoscopy plus conventional and modified clinical ABCD criteria (amelanotic, bleeding bump, colour uniformity, de novo at any diameter) improves diagnosis of paediatric melanoma (PM), suggests a recent study. Dermoscopy helps in differentiating spitzoid from nonspitzoid melanomas.

“On the basis of its clinical, dermoscopic and histopathological characteristics, PM can be classified as spitzoid or nonspitzoid,” according to researchers.

Nospitzoid melanomas (n=37; 72.3 percent) were detected in patients with a mean age of 16.3 years (range, 8‒20) and correlated with a high-risk phenotype and a pre-existing nevus (62.2 percent). Spitzoid melanomas (n=15; 27.7 percent) presented in patients at a mean age of 12.5 years (range, 2‒19) and were mostly de novo lesions (73.3 percent) located on the limbs (73.3 percent).

Less than one-fourth of PMs met the modified clinical ABCD criteria, but nearly half (40 percent) of spitzoid melanomas did. Dermoscopic melanoma criteria were found in all cases.

Nospitzoid melanomas were likely to be multicomponent (58.3 percent) or have nevus-like (25 percent) dermoscopic patterns. Spitzoid melanomas tended to have atypical vascular patterns with shiny white lines (46.2 percent) or an atypical pigmented spitzoid pattern (30.8 percent). A good correlation existed between spitzoid subtype histopathologically and dermoscopically (κ=0.66).

Researchers performed a retrospective study of 52 melanoma cases diagnosed in patients before the age of 20 years to analyse the clinicodermoscopic characteristics of PM. It was, however, limited by the failure to re-review the pathologic findings.

“Knowledge regarding the morphologic spectrum of PM is sparse, and this may in part contribute to delay in detection and thicker tumours,” researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
19 Sep 2018
In advanced-stage, newly diagnosed classical, CD30-positive Hodgkin lymphoma (HL), front-line therapy has resulted in durable remission rates in up to 70–90% of patients, although approximately 25–30% of advanced stage HL patients are refractory or relapse following first-line treatment with ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) chemotherapy.1–3 The standard of care for patients with relapsed or refractory (r/r) classical HL is salvage therapy using second-line high-dose chemotherapy (HDCT), followed by autologous haematopoietic stem cell transplant (ASCT) in eligible patients, which can induce a complete remission (CR) in about 50% of patients.4 Nevertheless, the prognosis of patients who relapse after the salvage HDCT/ASCT is exceedingly poor, with a median survival duration of approximately 1.2 years.5
09 Sep 2016
A German longitudinal study shows that Hodgkin’s lymphoma survivors experience acute and persistent fatigue regardless of tumour stage and treatment.
Natalia Reoutova, 6 days ago
Reduced conditioning intensity is significantly associated with increased relapse, decreased disease-free survival (DFS), and decreased overall survival (OS) in acute myeloid leukaemia (AML) patients with measurable residual disease (MRD), a new analysis of a phase III randomized clinical trial has shown.